TRIANGLE operation, combined with adequate adjuvant chemotherapy, can improve the prognosis of pancreatic head cancer: A retrospective study

Table 1 Demographic and clinicopathologic data

Variables	PDTRIANGLE (n = 52)	PDnon-TRIANGLE (n = 55)	P value
Age, median (IQR; yr)	69 (60-74)	67 (61-74)	0.589
Sex			0.154
Male	26 (50.0)	35 (63.6)
Female	26 (50.0)	20 (36.4)
BMI (mean ± SD, kg/m²)	22.86 ± 3.19	22.15 ± 2.79	0.224
ASA score			0.387
1	10 (19.6)	15 (27.3)
2	37 (72.6)	33 (60.0)
3	4 (7.8)	7 (12.7)
Main pancreatic duct size (mm)			0.208
≤ 3	18 (34.6)	19 (34.5)
> 3	34 (65.4)	36 (65.5)
CA19-9, median (IQR; IU/mL)	94.4 (37.3-358.5)	108.0 (57.6-213.2)	0.711
CEA, median (IQR; ng/mL)	3.4 (2.1-6.5)	3.9 (2.3-5.7)	0.521
Albumin (mean ± SD, g/L)	39.7 ± 3.9	40.7 ± 4.5	0.227
Serum bilirubin, median (IQR; μmol/L)	29.3 (8.3-186.4)	18.8 (9.4-114.9)	0.660
AJCC stage (8th ed)			0.291
I/IIa	28 (53.8)	24 (43.6)
IIb/III	24 (46.2)	31 (56.4)
Grading			0.385
1	2 (3.9)	0 (0.0)
2	39 (75.0)	45 (81.8)
3	11 (21.1)	10 (18.2)
PNI	44 (84.6)	44 (80.0)	0.532
PVI	28 (53.9)	27 (49.1)	0.623
Number of ELN, median (IQR)	20 (14-26)	14 (8-20)	0.001a
Margin status			0.579
R0	42 (80.8)	42 (76.4)
R1	10 (19.2)	13 (23.6)

^aP < 0.01.

Values in parentheses are percentages unless indicated otherwise. PD: Pancreaticoduodenectomy; IQR: interquartile range; BMI: Body mass index; ASA: American Society of Anesthesiologists; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; AJCC: American Joint Committee on Cancer; PNI: Perineural invasion; PVI: Perivascular invasion; ELN: Examined lymph nodes.